These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24897555)
21. Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy. Kuroda J; Mizutani S; Shimura Y; Maegawa S; Nagoshi H; Chinen Y; Tatekawa S; Tsukamoto T; Mizuno Y; Yamamoto-Sugitani M; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M Ann Hematol; 2015 Apr; 94(4):687-9. PubMed ID: 25209844 [No Abstract] [Full Text] [Related]
22. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
23. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447 [TBL] [Abstract][Full Text] [Related]
24. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Bladé J; Cibeira MT; Rosiñol L Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077 [TBL] [Abstract][Full Text] [Related]
26. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma. Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958 [TBL] [Abstract][Full Text] [Related]
27. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Balsas P; Galán-Malo P; Marzo I; Naval J Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467 [TBL] [Abstract][Full Text] [Related]
28. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799 [TBL] [Abstract][Full Text] [Related]
29. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Menu E; Garcia J; Huang X; Di Liberto M; Toogood PL; Chen I; Vanderkerken K; Chen-Kiang S Cancer Res; 2008 Jul; 68(14):5519-23. PubMed ID: 18632601 [TBL] [Abstract][Full Text] [Related]
30. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Dick LR; Fleming PE Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451 [TBL] [Abstract][Full Text] [Related]
31. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells. Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252 [TBL] [Abstract][Full Text] [Related]
32. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Manochakian R; Miller KC; Chanan-Khan AA Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333 [TBL] [Abstract][Full Text] [Related]
33. Bortezomib in the front-line treatment of multiple myeloma. Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451 [TBL] [Abstract][Full Text] [Related]
34. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479 [TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms. Uttenweiler-Joseph S; Bouyssié D; Calligaris D; Lutz PG; Monsarrat B; Burlet-Schiltz O Proteomics; 2013 Jan; 13(1):37-47. PubMed ID: 23135970 [TBL] [Abstract][Full Text] [Related]
36. Bortezomib and its role in the management of patients with multiple myeloma. Orlowski RZ Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047 [TBL] [Abstract][Full Text] [Related]
37. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676 [TBL] [Abstract][Full Text] [Related]
38. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. Broyl A; Jongen JL; Sonneveld P Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548 [TBL] [Abstract][Full Text] [Related]
39. Bortezomib in combination with other therapies for the treatment of multiple myeloma. Orlowski RZ J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424 [TBL] [Abstract][Full Text] [Related]
40. Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma. Cho Y; Hori M; Okoshi Y; Fujisawa F; Shinagawa A; Kudo D; Komeno T; Yoshida C; Katsura Y; Ota I; Shimizu S; Kamoshita M; Sasaki K; Tanaka K; Mukai HY; Kojima H Acta Haematol; 2015; 134(1):25-31. PubMed ID: 25871926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]